Caribou Biosciences (NASDAQ:CRBU) Posts Earnings Results, Beats Expectations By $0.01 EPS

Caribou Biosciences (NASDAQ:CRBU) released its earnings results on Monday. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.01, Zacks reports. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.

Caribou Biosciences Stock Down 4.7 %

Shares of CRBU stock traded down $0.06 during mid-day trading on Monday, reaching $1.11. The company’s stock had a trading volume of 859,858 shares, compared to its average volume of 1,655,743. The firm has a market capitalization of $100.06 million, a PE ratio of -0.67 and a beta of 2.34. The company’s 50 day simple moving average is $1.43 and its 200-day simple moving average is $1.81. Caribou Biosciences has a 12-month low of $1.01 and a 12-month high of $7.61.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on CRBU shares. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research note on Friday, November 15th. Citigroup lowered their target price on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Finally, Bank of America cut their price target on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $10.33.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.